LATEST NEWS

What about INMETRO

Date: 03/28/2019

A significant number of manufacturers that look for our regulatory services are not just searching for ANVISA registration services, their doubts are related to INMETRO certification processes and their requirements, which many times are not thoroughly discussed when planning a regulatory strategy for medical devices’ registration in Brazil. INMETRO is the National Institute of Metrology, Quality and Technology. It is responsible for executing the policies determined in the conformity assessment programs and it aims to improve the quality as well as ensure the safety of the products and services offered in Brazil.

Regarding the medical devices market, there are INMETRO ordinances which require certification for several different types of products, although it doesn’t apply to all types of medical devices. The ordinance determines the certification system, procedures and requirements such as:
· factory audit;
· testing (applicable standards);
· documentation needed;
· applicant audit (Brazilian Company);
· certification maintenance.

Products INMETRO Ordinance
Equipment under Sanitary Surveillance 54/2016
Hypodermic and Gingival Needles 501/2011
Sterile Hypodermic Syringes for Single Use 503/2011
Single Transfusion, Gravitational Infusion and 502/2011
Infusion equipment for use with Infusion Pump.
Surgical Gloves and Gloves for Non-Surgical 332/2012
Procedures under Sanitary Surveillance
Male Natural Rubber Latex Condoms 50/2002
Breast Implants 162/2012
The certification is performed by the accredited certification bodies.
The INMETRO certificate, issued by the certification body, is one of the documents that must be delivered over to ANVISA when requesting the registration of the medical devices listed above.
The certification requires time and energy from the regulatory specialists; choosing the right certification body to conduct the process is one of the first but most important steps.
If you decide to enter the Brazilian market and reckon INMETRO is one of the steps needed for the registration, our experts will be pleased to clarify any registration requirements and guide you through the process, avoiding surprises that might affect the product launching schedule.

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]